Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study - Report - MDSpire

Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study

  • By

  • Theresa Klinger

  • Katharina Müller

  • Ricarda Graf

  • Matthias Augustin

  • Kristina Hagenström

  • June 22, 2026

  • 0 min

Share

Time-Related Adverse Effects of Systemic Glucocorticosteroids in Atopic Dermatitis

Overview

This study investigates the association between the duration and cumulative dose of systemic glucocorticosteroids (SGCs) and the risk of adverse events in patients with atopic dermatitis (AD).

Background

Atopic dermatitis is a prevalent chronic condition. Despite guidelines recommending short-term use of systemic glucocorticosteroids for acute flare-ups, their overuse persists in clinical practice.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • Longer duration of SGC use correlates with increased adverse events in AD patients.
  • Adverse events include mental disorders, gastrointestinal disorders, osteoporosis, hypertension, and diabetes mellitus.
  • Duration of exposure shows more robust associations with adverse events than cumulative dose.

Clinical Implications

Clinicians should be aware of the risks associated with prolonged systemic glucocorticosteroid use in atopic dermatitis.

Conclusion

The study highlights the risks associated with prolonged systemic glucocorticosteroid use in atopic dermatitis.

Related Resources & Content

  1. American Academy of Dermatology, AAD, 2023 -- Atopic dermatitis clinical guideline
  2. Archives of Dermatological Research, 2026 -- The role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus
  3. Dermatology and Therapy — Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study
  4. Journal of Crohn's and Colitis — Comparative Analysis of Adverse Event Reporting for Corticosteroids in Inflammatory Bowel Disease: Insights from Reporting Systems and Patient Surveys
  5. Drugs - Real World Outcomes — Persistence and Maintenance Dosing of Ustekinumab in Crohn's Disease Patients: Analyzing Pre- and Post-Treatment Use of Corticosteroids and Opioids in the USA
  6. Journal of Crohn's and Colitis — Impact of concomitant corticosteroid use on adverse events in ulcerative colitis clinical trials
  7. Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study
  8. Comparative Analysis of Adverse Event Reporting for Corticosteroids in Inflammatory Bowel Disease
  9. Atopic dermatitis clinical guideline
  10. https://www.guidelines.edf.one/uploads/attachments/cm9grg5zd9dolrwjrnsrmzgju-0-atopic-eczema-gl-master-mar-2025.pdf
  11. Research article
  12. The role and risks of systemic corticosteroids in atopic dermatitis: an expert consensus | Archives of Dermatological Research | Springer Nature Link
  13. Systemic Corticosteroid Exposure in Patients with Atopic Dermatitis: A US Population-Based Study - PubMed
  14. Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis - PMC

Original Source(s)

Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study

  • by Theresa Klinger, Katharina Müller, Ricarda Graf, Matthias Augustin, Kristina Hagenström

  • June 22, 2026

Related Content

Predictive value of modified frailty index-5 to major complications after videothoracoscopic pulmonary resections

Football as the champion of cardiovascular prevention: results of the randomized and interventional MY-3F study (Fit & Fun with Football after myocardial infarction or coronary artery disease)

Weight Trajectory Impacts Risk for 10 Distinct Cardiometabolic Diseases